Celldex Therapeutics, Inc. (NASDAQ:CLDX) – Celldex Therapeutics Raises $250M Via Equity To Support Development Of Skin Disease Candidate

Celldex Therapeutics Raises $250M Via Equity To Support Development Of Skin Disease Candidate

  • Celldex Therapeutics Inc (NASDAQ: CLDX) has priced an underwritten public providing of round 5.9 million shares at $42.00 per share, representing a reduction of about 6% from the final shut worth of $44.6 on Tuesday.
  • Gross proceeds are anticipated to roughly $250 million.
  • The Firm beforehand introduced to offer $175 million in shares.
  • Underwriters have an choice to buy as much as an extra 892,857 shares.
  • Jefferies, SVB Leerink, Guggenheim Securities, and Cantor are performing because the joint book-running managers for the providing. 
  • LifeSci Capital LLC and H.C. Wainwright & Co. are performing as co-lead managers for the providing.
  • Celldex will use the proceeds to fund the event of CDX-0159 and for basic company functions.
  • The providing will shut by July 16.
  • Just lately, the Firm shared positive Phase 1b trial data of CDX-0159 in sufferers with antihistamine refractory chilly urticaria and symptomatic dermographism.
  • Value Motion: CLDX shares are down 2.65% at $43.42 premarket on the final test Wednesday.

https://www.benzinga.com/basic/biotech/21/07/21972966/celldex-therapeutics-raises-250m-via-equity-to-support-development-of-skin-disease-candidate?utm_source=feedburner&utm_medium=feed&utm_campaign=Feedpercent3A+benzinga+%28Benzinga+Information+Feedpercent29

snopx

Inter Reviewed is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – admin@interreviewed.com. The content will be deleted within 24 hours.

Related Articles

Back to top button